These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23787820)

  • 1. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Araie M;
    JAMA Ophthalmol; 2013 Oct; 131(10):1288-95. PubMed ID: 23787820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Araie M;
    Am J Ophthalmol; 2013 Oct; 156(4):731-6. PubMed ID: 23831221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers.
    Tanihara H; Inatani M; Honjo M; Tokushige H; Azuma J; Araie M
    Arch Ophthalmol; 2008 Mar; 126(3):309-15. PubMed ID: 18332309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
    JAMA Ophthalmol; 2015 Jul; 133(7):755-61. PubMed ID: 25880207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension.
    Williams RD; Novack GD; van Haarlem T; Kopczynski C;
    Am J Ophthalmol; 2011 Nov; 152(5):834-41.e1. PubMed ID: 21794845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
    Acta Ophthalmol; 2015 Jun; 93(4):e254-60. PubMed ID: 25487877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraocular pressure-lowering efficacy of brinzolamide when added to travoprost/timolol fixed combination as adjunctive therapy.
    Goldberg I; Crowston JG; Jasek MC; Stewart JA; Stewart WC;
    J Glaucoma; 2012 Jan; 21(1):55-9. PubMed ID: 21048504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits.
    Isobe T; Mizuno K; Kaneko Y; Ohta M; Koide T; Tanabe S
    Curr Eye Res; 2014 Aug; 39(8):813-22. PubMed ID: 24502505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular hypotensive efficacy, safety and systemic absorption of AR-12286 ophthalmic solution in normal volunteers.
    Kopczynski C; Novack GD; Swearingen D; van Haarlem T
    Br J Ophthalmol; 2013 May; 97(5):567-72. PubMed ID: 23435190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical and oral ketorolac administration increases the intraocular pressure-lowering effect of latanoprost.
    Costagliola C; Campa C; Perri P; Parmeggiani F; Romano MR; Incorvaia C
    Curr Eye Res; 2008 May; 33(5):477-82. PubMed ID: 18568885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Highly Selective Rho-Kinase Inhibitor (ITRI-E-212) Potentially Treats Glaucoma Upon Topical Administration With Low Incidence of Ocular Hyperemia.
    Hsu CR; Chen YH; Liu CP; Chen CH; Huang KK; Huang JW; Lin MN; Lin CL; Chen WR; Hsu YL; Lee TC; Chou SH; Tu CM; Hwang CS; Huang YC; Lu DW
    Invest Ophthalmol Vis Sci; 2019 Feb; 60(2):624-633. PubMed ID: 30735565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Long-Term Ripasudil 0.4% Instillation for the Reduction of Intraocular Pressure in Japanese Open-Angle Glaucoma Patients.
    Maruyama Y; Ikeda Y; Mori K; Yoshii K; Ueno M; Sotozono C; Kinoshita S
    J Ocul Pharmacol Ther; 2020 May; 36(4):229-233. PubMed ID: 32175792
    [No Abstract]   [Full Text] [Related]  

  • 15. Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy.
    Sato S; Hirooka K; Nitta E; Ukegawa K; Tsujikawa A
    Adv Ther; 2016 Sep; 33(9):1628-34. PubMed ID: 27438467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Topically Administered Rho-Kinase Inhibitor AR-12286 in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma.
    Skaat A; Jasien JV; Ritch R
    J Glaucoma; 2016 Sep; 25(9):e807-14. PubMed ID: 27552517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%.
    Katz G; Dubiner H; Samples J; Vold S; Sall K
    JAMA Ophthalmol; 2013 Jun; 131(6):724-30. PubMed ID: 23579344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy.
    Inazaki H; Kobayashi S; Anzai Y; Satoh H; Sato S; Inoue M; Yamane S; Kadonosono K
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2009-2015. PubMed ID: 28711991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular hypotensive safety and systemic absorption of AR-13324 ophthalmic solution in normal volunteers.
    Levy B; Ramirez N; Novack GD; Kopczynski C
    Am J Ophthalmol; 2015 May; 159(5):980-5.e1. PubMed ID: 25637177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
    Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
    Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.